Cargando…
Lung cancer screening: who pays? who receives?—the Chinese perspective
The National Lung Screening Trial (NLST) revealed that low-dose computed tomography (LDCT) screening reduced lung cancer mortality by 20.0%. In China, LDCT is very cheap and easy to access. As a result, LDCT screening is not limited to “high-risk” population defined by the NLST trial. The results of...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182701/ https://www.ncbi.nlm.nih.gov/pubmed/34164286 http://dx.doi.org/10.21037/tlcr.2020.03.16 |